FOR IMMEDIATE RELEASE

Elanco Launches Alternative to Shared-Class Antibiotics in Poultry Industry

GREENFIELD, Ind. May 19, 2016 — Elanco Animal Health introduces Inteprity™, a first-in-class, animal-use only, in-feed antibiotic developed for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler chickens. Under supervision of a veterinarian, Inteprity supports bird health and well-being, and demonstrates a responsible approach to antibiotic use.

Necrotic enteritis is a serious and constant threat to the health and welfare of poultry flocks. Due to the reduction of antibiotic use in poultry, the incidence of necrotic enteritis is on the rise, with daily mortality rates as high as 1 percent.1,2

“Inteprity helps promote healthy birds, and it also fits within antibiotic policies looking to reduce shared-class antibiotic use,” said Dr. Sara Steinlage, Poultry Technical Advisor at Elanco. “Inteprity is the first animal-use only antibiotic for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in poultry. Delivery of this important innovation also aligns with Elanco’s Eight-Point Antibiotic Stewardship Plan.”

In studies, Inteprity (avilamycin) reduced mortality due to necrotic enteritis between 76 to 93 percent versus the control group.3-5
“Elanco is dedicated to working with veterinarians and producers toward judicious antibiotic use, and our new animal-use only antibiotic solution is a step in the right direction,” said Steinlage. “Administered using a Veterinary Feed Directive, Inteprity offers mortality prevention while also promoting judicious antibiotic use with veterinarian oversight.”

Visit Elanco.us/Inteprity for more information.

###

About Elanco:
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com

For the prevention of mortality caused by necrotic enteritis associated with *Clostridium perfringens* in broiler chickens:
- Avilamycin is to be fed at 13.6 to 40.9 grams per ton of Type C medicated feed (15 to 45 ppm) as the sole ration for 21 consecutive days.
- Feed to chickens that are at risk of developing, but not yet showing clinical signs of, necrotic enteritis associated with *Clostridium perfringens*.

Important Safety Information
- **CAUTION:** Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
- To assure responsible antimicrobial drug use in broiler chickens, treatment administration must begin on or before 10 days of age.
- The safety of avilamycin has not been established in chickens intended for breeding purposes.
- Avilamycin has not been demonstrated to be effective in broiler chickens showing clinical signs of necrotic enteritis prior to the start of medication.
- The Veterinary Feed Directive (VFD) expiration date must not exceed 90 days from the date of issuance. VFDs for avilamycin shall not be refilled.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Inteprity for the prevention of mortality caused by necrotic enteritis associated with *Clostridium perfringens* in broiler chickens, and reflects Lilly’s and Elanco’s current belief. However, as with any animal health product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Inteprity will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange
Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.


Elanco®, Inteprity™ and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
© 2016 Eli Lilly and Company, its subsidiaries or affiliates.
USPBUITY00011(2)